Ventyx Biosciences, (id:7571 VTYX)
1.85 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 7:01:19 AM)
Exchange closed, opens in 1 day 2 hours
About Ventyx Biosciences,
Market Capitalization 132.23M
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
| Headquarters (address) |
12790 El Camino Real San Diego 92130 CA United States |
| Phone | 760 593 4832 |
| Website | https://ventyxbio.com |
| Employees | 79 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | VTYX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.67 - 11.48 |
| Market Capitalization | 132.23M |
| P/E trailing | -0.561 |
| P/E forward | -0.870 |
| Price/Book | 0.474 |
| Beta | 0.366 |
| EPS | -2.35 |
| EPS United States (ID:6, base:3402) | 24.22 |